These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 39147035)
1. Undetectable PSA predicts outcome after salvage radiotherapy for biochemical recurrence following radical prostatectomy. Scharl S; Gartner L; Böhmer DHG; Siegmann A; Thamm R; Krafcsik M; Mayer B; Zips D; Ruf C; Wiegel T Radiother Oncol; 2024 Nov; 200():110476. PubMed ID: 39147035 [TBL] [Abstract][Full Text] [Related]
2. Salvage radiotherapy in patients with persistently detectable PSA or PSA rising from an undetectable range after radical prostatectomy gives comparable results. Lohm G; Bottke D; Jamil B; Miller K; Neumann K; Bartkowiak D; Hinkelbein W; Wiegel T World J Urol; 2013 Apr; 31(2):423-8. PubMed ID: 22460203 [TBL] [Abstract][Full Text] [Related]
3. Outcomes of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. Lee EK; Mui WH; Chan AW; Tung Y; Wong FC Hong Kong Med J; 2018 Jun; 24(3):218-225. PubMed ID: 29807949 [TBL] [Abstract][Full Text] [Related]
4. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. Preisser F; Chun FKH; Pompe RS; Heinze A; Salomon G; Graefen M; Huland H; Tilki D Eur Urol; 2019 Jul; 76(1):106-114. PubMed ID: 30772034 [TBL] [Abstract][Full Text] [Related]
6. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study. Wiegel T; Lohm G; Bottke D; Höcht S; Miller K; Siegmann A; Schostak M; Neumann K; Hinkelbein W Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1009-16. PubMed ID: 18963539 [TBL] [Abstract][Full Text] [Related]
7. Clinical Outcome of Salvage Radiotherapy for Locoregional Clinical Recurrence After Radical Prostatectomy. Lee SU; Cho KH; Kim JH; Kim YS; Nam TK; Kim JS; Cho J; Choi SH; Shim SJ; Kim JH; Chang AR Technol Cancer Res Treat; 2021; 20():15330338211041212. PubMed ID: 34806469 [No Abstract] [Full Text] [Related]
8. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176 [TBL] [Abstract][Full Text] [Related]
9. The impact of salvage radiotherapy initiation at PSA ≤ 0.5 ng/ml on metastasis-free survival in patients with relapsed prostate cancer following prostatectomy. Lee EE; Singh T; Hu C; Han M; Deville CJ; Halthore A; Greco S; Tran P; DeWeese T; Song DY Prostate; 2023 Feb; 83(2):190-197. PubMed ID: 36316967 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy. Oehus AK; Kroeze SGC; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M; Christiansen H; Henkenberens C BMC Cancer; 2020 Apr; 20(1):362. PubMed ID: 32349700 [TBL] [Abstract][Full Text] [Related]
11. Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy : Informing the debate. Budäus L; Schiffmann J; Graefen M; Huland H; Tennstedt P; Siegmann A; Böhmer D; Budach V; Bartkowiak D; Wiegel T Strahlenther Onkol; 2017 Sep; 193(9):692-699. PubMed ID: 28470414 [TBL] [Abstract][Full Text] [Related]
12. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy. Rogowski P; Trapp C; von Bestenbostel R; Eze C; Ganswindt U; Li M; Unterrainer M; Zacherl MJ; Ilhan H; Beyer L; Kretschmer A; Bartenstein P; Stief C; Belka C; Schmidt-Hegemann NS Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1417-1428. PubMed ID: 34628521 [TBL] [Abstract][Full Text] [Related]
13. The PSA-response to salvage radiotherapy after radical prostatectomy correlates with freedom from progression and overall survival. Bartkowiak D; Bottke D; Thamm R; Siegmann A; Hinkelbein W; Wiegel T Radiother Oncol; 2016 Jan; 118(1):131-5. PubMed ID: 26653358 [TBL] [Abstract][Full Text] [Related]
14. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249 [TBL] [Abstract][Full Text] [Related]
15. Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience. Murgic J; Jaksic B; Prpic M; Kust D; Bahl A; Budanec M; Prgomet Secan A; Franco P; Kruljac I; Spajic B; Babic N; Kruslin B; Zovak M; Zubizarreta E; Rosenblatt E; Fröbe A Radiat Oncol; 2021 May; 16(1):88. PubMed ID: 33980277 [TBL] [Abstract][Full Text] [Related]